The 36-month beta value for ETON is at 1.28. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ETON is 24.41M, and currently, shorts hold a 0.61% of that float. The average trading volume for ETON on May 10, 2024 was 60.33K shares.
ETON) stock’s latest price update
The stock of Eton Pharmaceuticals Inc (NASDAQ: ETON) has decreased by -7.66 when compared to last closing price of 3.72.Despite this, the company has seen a loss of -8.40% in its stock price over the last five trading days. GlobeNewsWire reported 2024-05-01 that DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows:
ETON’s Market Performance
ETON’s stock has fallen by -8.40% in the past week, with a monthly rise of 0.15% and a quarterly drop of -22.11%. The volatility ratio for the week is 5.07% while the volatility levels for the last 30 days are 6.03% for Eton Pharmaceuticals Inc The simple moving average for the last 20 days is 0.56% for ETON’s stock, with a simple moving average of -15.37% for the last 200 days.
Analysts’ Opinion of ETON
Many brokerage firms have already submitted their reports for ETON stocks, with Craig Hallum repeating the rating for ETON by listing it as a “Buy.” The predicted price for ETON in the upcoming period, according to Craig Hallum is $8 based on the research report published on May 06, 2024 of the current year 2024.
B. Riley Securities, on the other hand, stated in their research note that they expect to see ETON reach a price target of $10. The rating they have provided for ETON stocks is “Buy” according to the report published on October 14th, 2021.
H.C. Wainwright gave a rating of “Buy” to ETON, setting the target price at $15 in the report published on January 04th of the previous year.
ETON Trading at -8.45% from the 50-Day Moving Average
After a stumble in the market that brought ETON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.88% of loss for the given period.
Volatility was left at 6.03%, however, over the last 30 days, the volatility rate increased by 5.07%, as shares sank -0.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.33% lower at present.
During the last 5 trading sessions, ETON fell by -8.40%, which changed the moving average for the period of 200-days by +25.82% in comparison to the 20-day moving average, which settled at $3.42. In addition, Eton Pharmaceuticals Inc saw -21.58% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ETON
Current profitability levels for the company are sitting at:
- 0.05 for the present operating margin
- 0.72 for the gross margin
The net margin for Eton Pharmaceuticals Inc stands at 0.06. The total capital return value is set at 0.08. Equity return is now at value -6.56, with -3.30 for asset returns.
Based on Eton Pharmaceuticals Inc (ETON), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at 1.6. The debt to equity ratio resting at 0.34. The interest coverage ratio of the stock is 12.3.
Currently, EBITDA for the company is -6.49 million with net debt to EBITDA at -5.29. When we switch over and look at the enterprise to sales, we see a ratio of 2.19. The receivables turnover for the company is 9.39for trailing twelve months and the total asset turnover is 1.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.65.
Conclusion
In conclusion, Eton Pharmaceuticals Inc (ETON) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
